GOLGA6D Inhibitors
GOLGA6D inhibitors encompass a specialized category of chemical compounds designed to selectively interfere with the activity of the GOLGA6D protein. GOLGA6D, a member of the golgin subfamily of proteins, is implicated in the maintenance and function of the Golgi apparatus, a critical organelle involved in protein sorting and modification. The precise modulation of GOLGA6D is crucial for the proper functioning and structural integrity of the Golgi apparatus. Inhibitors targeting this protein work by disrupting its ability to bind to other molecular components within the cell, thereby impeding its role in Golgi apparatus maintenance. These compounds typically exert their function by binding to specific domains of the GOLGA6D protein, which can interfere with its normal interactions and lead to alterations in Golgi morphology or function. Given the essential role of the Golgi apparatus in cellular operations, the inhibition of GOLGA6D has profound effects on intracellular transport and the lifecycle of proteins that transit through this organelle.
In terms of their biochemical mechanisms, GOLGA6D inhibitors may function by directly binding to the active or binding sites of the GOLGA6D protein, thereby blocking its interaction with other golgin proteins and disrupting the tethering function that is essential for maintaining Golgi structure. Alternatively, these inhibitors might prevent post-translational modifications of GOLGA6D that are necessary for its function, such as phosphorylation or acetylation. By impeding these modifications, the inhibitors effectively reduce the functional capacity of GOLGA6D, leading to a cascade of intracellular effects that can alter Golgi-mediated processes such as protein trafficking, glycosylation, and cell signaling. The specificity of these inhibitors is critical, as it ensures that the impact on GOLGA6D does not inadvertently affect other golgins or unrelated proteins with similar domains. This specificity is achieved through the careful design of inhibitor molecules that closely match the unique structural features of GOLGA6D, ensuring that the effects on the Golgi apparatus and cellular function are as targeted as possible.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Since GOLGA6D is involved in the Golgi apparatus and may be linked to vesicular trafficking, hydroxychloroquine's action can indirectly affect the function of GOLGA6D by disrupting the acidic environment required for Golgi apparatus function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
A fungal metabolite that inhibits protein transport from the endoplasmic reticulum to the Golgi apparatus. By preventing this transport, Brefeldin A indirectly inhibits GOLGA6D by disrupting the proper functioning and maintenance of the Golgi apparatus. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
An ionophore that disrupts Golgi function by altering ion gradients. Since GOLGA6D is associated with the Golgi apparatus, this disruption can inhibit its proper localization and function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
An inhibitor of N-linked glycosylation that blocks the formation of protein glycosylation in the endoplasmic reticulum. GOLGA6D's function can be indirectly inhibited due to impaired glycosylation processes vital for proper protein folding and trafficking to the Golgi. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
A specific inhibitor of the Golgi BFA-resistant guanine nucleotide exchange factor 1 (GBF1). By targeting GBF1, Golgicide A can indirectly inhibit GOLGA6D by compromising the integrity and function of the Golgi apparatus. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
An inhibitor of Golgi alpha-mannosidase II, which is essential for N-linked glycosylation. Swainsonine's inhibition of glycosylation processes can indirectly affect GOLGA6D function by disrupting protein processing and trafficking. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
A glucosidase inhibitor that interferes with N-linked glycosylation. Similar to Swainsonine, castanospermine can indirectly inhibit GOLGA6D by altering glycosylation pathways essential for Golgi apparatus function. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
A microtubule destabilizer that can disrupt intracellular transport processes. Since GOLGA6D is implicated in vesicular transport, nocodazole's action can indirectly inhibit GOLGA6D by impeding protein trafficking to and within the Golgi. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Another microtubule destabilizing agent which can impair vesicular and organelle motility. As GOLGA6D is related to the Golgi apparatus, colchicine can inhibit its function by affecting microtubule-dependent transport processes. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
A matrix metalloproteinase inhibitor that can affect intracellular trafficking and extracellular matrix interactions. Though not directly linked, it may indirectly affect GOLGA6D function through altered intracellular matrix signaling that can influence Golgi apparatus dynamics. | ||||||